Business Context and Reporting Period
Company: IOVANCE BIOTHERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2026
Reporting Period: Single event date (August 6, 2026)
Business Context: The filing serves to notify the market of an update to the Company's corporate presentation materials used for healthcare conferences, analyst meetings, and stockholder communications.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of a corporate event (presentation update) and does not contain financial statements or performance metrics.
Material Changes
Corporate Presentation Update: On August 6, 2026, the Company updated its corporate presentation. The updated document is attached as Exhibit 99.1 and is incorporated by reference. No other material changes to operations, financial condition, or corporate structure are disclosed in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no specific management commentary, financial guidance, or outlook beyond the reference to the attached corporate presentation.
Risks and Contingencies: No new risks or contingencies are disclosed in the text of this filing.
Unusual Items: None reported.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation – August 2026) for updated strategic data, clinical trial timelines, or financial projections not detailed in the 8-K text.
- Verify the role of Frederick G. Vogt, Ph.D., J.D., who signed the report as Interim CEO and President, and General Counsel.
- Confirm the trading symbol IOVA on The Nasdaq Stock Market, LLC.
- Check for subsequent filings if the corporate presentation contains forward-looking statements requiring further disclosure.